this post was submitted on 04 May 2025
34 points (100.0% liked)

Canada

9733 readers
1077 users here now

What's going on Canada?



Related Communities


🍁 Meta


🗺️ Provinces / Territories


🏙️ Cities / Local Communities

Sorted alphabetically by city name.


🏒 SportsHockey

Football (NFL): incomplete

Football (CFL): incomplete

Baseball

Basketball

Soccer


💻 Schools / Universities

Sorted by province, then by total full-time enrolment.


💵 Finance, Shopping, Sales


🗣️ Politics


🍁 Social / Culture


Rules

  1. Keep the original title when submitting an article. You can put your own commentary in the body of the post or in the comment section.

Reminder that the rules for lemmy.ca also apply here. See the sidebar on the homepage: lemmy.ca


founded 4 years ago
MODERATORS
 

cross-posted from: https://rss.ponder.cat/post/173363

Health Canada said the mix-up could cause patients to get a larger dose of painkiller than prescribed, possibly resulting in an overdose with 'potentially fatal health risks.'


From this RSS feed

top 3 comments
sorted by: hot top controversial new old
[–] [email protected] 5 points 4 weeks ago

i mean… that’s ONE way to stop the pain…

[–] [email protected] 4 points 4 weeks ago* (last edited 4 weeks ago)

I have a headache.

Gulp

🎶 Goooolden broooown, texture like suuuun 🎶

[–] [email protected] 4 points 4 weeks ago

JAMP Pharma Corp., a Quebec pharmaceutical maker, is recalling one lot of JAMP-Pregabalin pain medicine because bottles labelled to contain 50-milligram capsules may contain 150-milligram capsules instead.

Health Canada announced the recall in an unusual Saturday evening statement.

The announcement said the company’s mix-up could lead to patients taking a much larger dose of the painkiller than prescribed, possibly resulting in an overdose that could “pose serious, potentially fatal health risks.”

JAMP-Pregabalin is an adult prescription drug. It is used to treat pain caused by nerve damage due to diabetes, shingles or spinal cord injury. It is also used to treat pain associated with fibromyalgia, Health Canada said.

The recall affects one lot of the 50-mg capsules bearing lot number 2305012747, which carries a 2026-08 expiry date, Health Canada said.

Health Canada stressed that taking too much pregabalin or suddenly increasing the dose could potentially lead to patients overdosing, which can be life-threatening.